Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 4;14:1707–1718. doi: 10.2147/OTT.S300623

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Pharmacological targeting of CAXII in glioma in vitro functional responses. 6A10 treatment did cause mild inhibitory effect on cell growth in subset of tested GSC models/GBM1 and BTSC407, and no effect on BTSC233, unb = control (A–C). All cells are IDH1wt and MGMT promoter methylated, GBM1 and 407 are classical subtype of GBM, BTSC233 is mesenchymal subtype of GBM (data not shown). 6A10 treatment caused suppression of cellular invasion in responder cell line GBM1 but not in non-responder model 407 (D and E), BTSC233 not tested.